SCHEMBL20964637

SCHEMBL20964637

Cc1cc(CSc2ccccc2C(=O)N2CCN(c3ncccn3)CC2)on1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
RXFP1 Q9HBX9 1/20 0.56
ALDH1A1 P00352 6/20 0.54
TSHR P16473 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KDM4E B2RXH2 5/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PKM P14618 1/20 0.49
SLC6A7 Q99884 1/20 0.47
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964548 0.90 ALDH1A1 (0.59) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL20964553 0.88 ALDH1A1 (0.69) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL20964636 0.85 SMN1; SMN2 (0.53) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL20964599 0.85 LMNA (0.59) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL20964683 0.85 LMNA (0.53) LMNAKMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL20964655 0.84 LMNA (0.52) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL20964665 0.84 LMNA (0.62) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL20965377 0.84 LMNA (0.58) LMNAMEN1KMT2ARXFP1ALDH1A1
SCHEMBL20964705 0.83 ALDH1A1 (0.49) LMNAMEN1KMT2ARXFP1ALDH1A1
SCHEMBL20964690 0.82 ALDH1A1 (0.79) LMNAMEN1KMT2ARXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 LMNA 1413/4885MEN1 179/4885KMT2A 4728/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 LMNA 897/4885MEN1 2387/4885KMT2A 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.